Literature Database for Discrete Element Method Simulation Available Online - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Literature Database for Discrete Element Method Simulation Available Online


DEM Solutions made available an extensive, searchable, online library of abstracts of peer-reviewed papers on the development and application of discrete element method (DEM) simulation for modeling bulk particle processes, the company announced in a press release.

The resource has been available to DEM Solutions' customers and academic users and is now publicly available. “With growing interest in deploying DEM simulation across many of the manufacturing and process industries, we wanted to open up access to non-customers as well in order to foster innovation and new application areas,” said John Favier, PhD, CEO of DEM Solutions, in the press release.

The DEM Literature Database currently includes abstracts of over 3000 papers and is searchable by title, author, keywords, publisher, and year of publication, including links to publication sources where the full-text papers can be obtained. The database includes papers published from 2001 through early 2013 and will be updated regularly as new papers are made available.

“We want to make it much easier for those in commercial R&D and academic research to find out about the latest DEM developments, as well as to locate previous studies using similar methodology or addressing the same engineering challenges,” said Favier. “Visitors can follow the work of thousands of DEM researchers over the last decade or explore the progression of DEM deployment within an industry vertical or engineering discipline.”

DEM Solutions commented on DEM simulation in the pharmaceutical industry in a recent Pharmaceutical Technology article, “Developments in Pharmaceutical Process Modeling.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here